trending Market Intelligence /marketintelligence/en/news-insights/trending/na5pwymc4q7z4cc6bez-xa2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Abbvie to continue manufacturing component for lymphoma drug

Street Talk Episode 52 - A bank's 'knife fight' to stay high performing in a low rate environment

Streaming Media Devices Feel The Squeeze In Q3'19

AT&T To Use Wireless Subs To Create Buzz For HBO

Municipal CUSIP Requests On Pace For Record Year, Thanks To October Issuance Surge


Abbvie to continue manufacturing component for lymphoma drug

Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.

The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.

Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.